Clinical Trial Liability Insurance

What the coverage does

This coverage responds in two distinct ways: a third-party liability component for claims alleging negligence in the design or conduct of the trial, and a no-fault subject injury compensation benefit that pays covered medical costs to a participant injured during the study regardless of fault. Many institutional review boards and ethics committees require evidence of the no-fault benefit before approving a protocol.

Sponsors, CROs, and individual investigator sites can each carry distinct exposure, and a single trial often involves coverage placed at the sponsor level with site-level protections layered underneath.

A typical claim scenario involves a participant experiencing an unexpected adverse reaction during a phase two trial; the no-fault benefit pays the participant's covered medical costs immediately regardless of fault, while a separate third-party liability claim might later allege the informed consent process failed to adequately disclose the known risk profile of the investigational compound.

Who needs it

Pharmaceutical and biotech sponsors, contract research organizations managing multi-site trials, academic medical centers running investigator-initiated studies, and device manufacturers conducting clinical evaluations are the primary buyers.

Decentralized trial sponsors using at-home visit vendors and wearable monitoring devices should also confirm this coverage addresses the added handoff points between the sponsor, the site, and any third-party vendor collecting data outside a traditional clinical setting.

What it covers and excludes in practice

Coverage typically extends to bodily injury directly attributable to the investigational product or study procedure, adverse events documented under the protocol, and third-party negligence claims against the sponsor or site. Most policies exclude the participant's pre-existing condition worsening independent of the study, off-protocol use of the investigational product, and claims arising from a site's failure to follow the approved protocol where that failure is treated as a separate exclusion.

No-fault subject injury benefits are typically capped per incident and are separate from the liability limit, so sponsors should confirm both figures rather than assuming one governs the other.

What drives price and how to structure it

Underwriters price this line based on trial phase, therapeutic area, number of subjects and sites, geographic scope, and the nature of the investigational product. Multi-country trials typically require coordinated placements across jurisdictions, and sponsors should structure limits to satisfy the strictest local regulatory requirement among the countries involved.

No-fault subject injury benefits are typically structured with a per-participant cap and sometimes a per-incident aggregate, and sponsors running large multi-site studies should confirm whether the aggregate is sized to a worst-case scenario in which an entire study cohort experiences a related adverse event tied to the investigational product.